United States Patent 10,639,309: Tofacitinib Extended-Release Dosage Form Patent Scope and Landscape

U.S. Patent No. 10,639,309 protects once-daily, osmotic-release tofacitinib dosage forms containing 22 mg of tofacitinib or an equivalent pharmaceutically acceptable salt. The patent focuses on a combination of structural formulation elements and pharmacokinetic or dissolution performance limits. Its practical scope reaches formulations using a semipermeable, cellulose-derivative membrane, an osmagen, and release profiles designed to approximate twice-daily immediate-release tofacitinib exposure.

The broadest independent claims are claims 1, 2, and 8. Claims 2 and 8 are particularly significant because they define the invention partly through clinical pharmacokinetic results rather than only through tablet architecture.

What does U.S. Patent 10,639,309 protect?

The patent protects a once-daily sustained-release tofacitinib dosage form with five core requirements:

A dosage-form core containing 22 mg of tofacitinib, or an equivalent salt amount.
An osmagen in the core.
A semipermeable membrane surrounding the core.
A water-insoluble polymer in the membrane, specifically a cellulose derivative.
Drug delivery primarily driven by osmotic pressure.

The claims also impose dissolution, exposure, concentration-ratio, food-effect, and time-above-threshold limitations.

Claim group	Principal limitation	Claim type
Claim 1	22 mg core, osmagen, semipermeable cellulose-derivative membrane, defined dissolution profile	Formulation and in vitro performance
Claims 2-7	22 mg core with exposure comparable to 10 mg immediate-release tofacitinib twice daily	Formulation and pharmacokinetic performance
Claims 8-16	Dose-normalized AUC, Cmax/Cmin ratio, concentration thresholds, and Cmax	Formulation and pharmacokinetic performance
Claims 17-23	Osmotic platform, cellulose acetate, water-soluble polymer, and sorbitol	Structural formulation limitations
Claims 24-25	Low Cmin and limited fed/fasted variability	Pharmacokinetic and food-effect limitations

The patent does not cover every extended-release tofacitinib product. A competing product would generally need to satisfy all limitations of at least one asserted claim, either literally or under an applicable doctrine-of-equivalents theory.

How broad are independent claims 1, 2, and 8?

Claim 1: dissolution-defined osmotic dosage form

Claim 1 is the most formulation-oriented independent claim. It requires:

22 mg of tofacitinib or equivalent salt;
an osmagen;
a semipermeable membrane;
a water-insoluble cellulose derivative;
primary osmotic delivery; and
a specific dissolution profile.

The dissolution limits are:

Test time	Required dissolved tofacitinib
1 hour	Not more than 30%
2.5 hours	At least 35% and not more than 75%
5 hours	At least 75%

The test uses 900 mL of 0.05 M potassium phosphate buffer at pH 6.8, 37°C, and a USP rotating-paddle apparatus at 50 rpm.

This claim creates a measurable infringement screen. A generic manufacturer could test a proposed product against the specified dissolution conditions. A formulation outside any one of the stated dissolution bands would have a defense against literal infringement of claim 1, although it could remain exposed under claims 2 or 8 if its clinical pharmacokinetics fall within those claims.

Claim 2: exposure-equivalence claim

Claim 2 requires the same basic osmotic formulation architecture but defines performance against 10 mg of immediate-release tofacitinib administered twice daily.

The required parameters are:

AUC between 80% and 125% of the twice-daily immediate-release reference;
geometric mean Cmax-to-Cmin ratio from approximately 10 to 100; and
primary osmotic delivery through a cellulose-derivative membrane.

The claim does not require the claim 1 dissolution profile. A product may therefore avoid claim 1 while potentially falling within claim 2.

Dependent claims narrow the pharmacokinetic window:

Claim	Narrowed limitation
3	AUC of 90%-110%; Cmax/Cmin ratio of about 20-40
4	Cmax/Cmin ratio of about 20-30
5	Mean Cmax of 70%-125% of immediate-release BID Cmax
6	Drug holiday of 80%-110% of the immediate-release BID drug holiday
7	Drug holiday of approximately 15-18 hours

Claim 8: dose-normalized exposure claim

Claim 8 requires:

22 mg of tofacitinib or equivalent salt;
an osmagen;
a semipermeable membrane;
a water-insoluble cellulose derivative;
primary osmotic delivery;
mean AUC of approximately 17-42 ng·hr/mL per mg dosed; and
geometric mean Cmax/Cmin ratio of about 10-100.

Claims 9 and 10 narrow the Cmax/Cmin ratio to approximately 20-40 and 20-30, respectively. Claims 11-16 add concentration-time limits and a dose-normalized Cmax range of approximately 3-6 ng/mL per mg.

Claim 8 is potentially important in a product challenge because it uses dose-normalized pharmacokinetic parameters. A manufacturer cannot avoid the claim merely by changing the tablet strength if the resulting product still contains the claimed 22 mg dose and satisfies the pharmacokinetic limitations.

What formulation technologies are covered?

Osmotic delivery systems

Claim 17 identifies three delivery platforms:

extrudable core systems;
swellable core systems; and
asymmetric membrane technology.

Because claim 17 depends on claim 8, the platform limitation does not stand alone. A product must also satisfy the claim 8 dose, polymer, osmotic-delivery, and pharmacokinetic requirements.

The central technical concept is a core that uses an osmagen to generate osmotic pressure after water enters through the semipermeable membrane. The membrane controls water influx and drug release. The claims require the dosage form to deliver tofacitinib primarily through osmotic pressure, which distinguishes the claimed products from conventional hydrophilic matrix tablets, multiparticulate systems, and purely diffusion-controlled coatings.

Cellulose-derivative membranes

Claim 18 specifically identifies cellulose acetate. The broader independent claims refer to a cellulose derivative. Potentially relevant polymers include cellulose acetate and other water-insoluble cellulose derivatives, depending on the specification’s definitions and construction.

A formulation using a non-cellulosic water-insoluble membrane polymer may avoid the literal cellulose-derivative limitation. It may still face an equivalence argument, but the technical and legal case would depend on the patent’s prosecution history, claim amendments, and prior-art distinctions.

Water-soluble coating polymers

Claim 19 adds a water-soluble polymer with an average molecular weight between 2,000 and 100,000 daltons. Claim 20 lists:

water-soluble cellulose derivatives;
acacia;
dextrin;
guar gum;
maltodextrin;
sodium alginate;
starch;
polyacrylates; and
polyvinyl alcohols.

Claim 21 narrows the cellulose derivative to hydroxypropylcellulose, hydroxypropylmethylcellulose, or hydroxyethylcellulose.

These claims cover membrane formulations that combine a water-insoluble cellulose derivative with a water-soluble pore-forming or permeability-modifying polymer.

Osmagens

Claim 22 requires a sugar as the osmagen, and claim 23 specifies sorbitol. The claims therefore reach formulations in which sorbitol generates or contributes to the osmotic driving force.

A formulation using sodium chloride, another inorganic osmotic agent, or a non-sugar organic osmagen may avoid claims 22 and 23 but could remain within independent claims 1, 2, or 8 if it meets their broader osmagen limitations.

What pharmacokinetic profile does the patent require?

The patent is directed to once-daily exposure that approximates immediate-release tofacitinib administered twice daily.

The principal pharmacokinetic limitations include:

Parameter	Claimed range
AUC versus 10 mg immediate-release BID	80%-125%
Narrower AUC range	90%-110%
Geometric mean Cmax/Cmin	About 10-100
Narrower Cmax/Cmin range	About 20-40 or 20-30
Mean Cmax versus immediate-release BID	70%-125%
Dose-normalized AUC	About 17-42 ng·hr/mL/mg
Dose-normalized Cmax	About 3-6 ng/mL/mg
Mean steady-state Cmin	Less than about 0.3 ng/mL/mg
Single continuous time above 17 ng/mL	About 6-15 hours
Single continuous time below 17 ng/mL	About 9-18 hours
Drug holiday	Approximately 15-18 hours under claim 7
Mean fed/fasted AUC ratio	About 0.7-1.4
Mean fed/fasted Cmax ratio	About 0.7-1.4

The “drug holiday” limitation is commercially relevant. It describes the period during which plasma tofacitinib concentration remains below a specified pharmacologic threshold. The patent therefore seeks a once-daily product that provides a high peak, a prolonged decline, and a substantial low-concentration interval before the next dose.

What is the patent’s likely relationship to Xeljanz and Xeljanz XR?

Tofacitinib is marketed by Pfizer under the Xeljanz and Xeljanz XR brands. Xeljanz is an immediate-release formulation, while Xeljanz XR is an extended-release formulation intended for once-daily administration. The claimed 22 mg dose aligns with a once-daily extended-release strength used in certain treatment regimens, while the claims also define exposure against the 10 mg immediate-release twice-daily regimen.

The product-level relevance depends on whether U.S. Patent No. 10,639,309 is listed for the applicable Xeljanz XR strength and indication in the FDA Orange Book, and whether the marketed product’s approved labeling identifies the patented dosage form. Orange Book listing and infringement are separate issues. Listing creates a statutory patent-certification framework for an ANDA, but it does not establish validity or prove that every marketed product practices every claim. FDA’s Orange Book identifies listed patents and exclusivity information; it does not adjudicate claim scope or patent validity (FDA, 2024).

When does U.S. Patent 10,639,309 expire?

The patent issued on May 5, 2020. Its expiration date cannot be determined from the claim text alone because U.S. patent term depends on the relevant nonprovisional filing date, priority chain, terminal disclaimers, patent-term adjustment, and any patent-term extension.

The patent’s effective term should therefore be calculated from the USPTO bibliographic record and patent-term data, not inferred from the grant date. A terminal disclaimer would be especially important if the patent is a continuation or continuation-in-part related to other tofacitinib patents.

The key term variables are:

Term variable	Relevance
Earliest effective nonprovisional filing date	Establishes the ordinary 20-year term base
Priority applications	Determine continuity but do not automatically set the expiration date
Patent-term adjustment	May extend the base term
Terminal disclaimer	May cut the term back to an earlier patent’s expiration
Patent-term extension	May extend the term for regulatory review, if granted
Patent-term disclaimer or disclaimer status	Can materially change enforceable life

How strong is the patent estate for generic entry?

The patent has moderate-to-strong claim value against a generic that attempts to duplicate the branded once-daily osmotic product. Its strength comes from the combination of structural and performance limitations.

Strengths

The 22 mg dose narrows the commercial target.
The osmagen and semipermeable membrane requirements identify a recognizable technology.
Cellulose-derivative membrane limitations may map directly to commercial osmotic designs.
Claims 1, 2, and 8 use different infringement pathways.
Claims 2 and 8 can capture products through pharmacokinetic results even if their dissolution profile differs.
Claims 17-23 provide narrower fallback positions for specific platforms, polymers, and osmagens.
Food-effect limitations in claim 25 address a commercial performance attribute that may be difficult to design around without new clinical data.

Vulnerabilities

The claims are vulnerable to anticipation or obviousness attacks based on earlier osmotic delivery patents combined with prior tofacitinib pharmacokinetic disclosures.
Pharmacokinetic limitations can create reproducibility and claim-construction disputes.
“Primarily by osmotic pressure” may require technical evidence regarding the dominant release mechanism.
The 22 mg requirement may exclude lower-strength products.
A generic may design around the cellulose-derivative limitation using a different membrane chemistry.
A generic may use a non-osmotic matrix or multiparticulate system.
A product outside the specified PK intervals may avoid the performance claims even if it is once daily.

What Paragraph IV challenges and litigation risks exist?

A generic applicant seeking approval before patent expiration would need to address any Orange Book-listed patent through a Paragraph IV certification, a Section viii statement where appropriate, or another statutory pathway under the Hatch-Waxman framework. A Paragraph IV certification can trigger patent litigation if the patent owner files suit within the statutory period after receiving notice (21 U.S.C. § 355(j)(2)(A)(vii)(IV); 35 U.S.C. § 271(e)(2)).

For this patent, likely litigation issues would include:

Whether the proposed product contains 22 mg of tofacitinib or an equivalent salt amount.
Whether its membrane contains a qualifying cellulose derivative.
Whether release is primarily osmotic.
Whether the product satisfies the dissolution bands in claim 1.
Whether the product satisfies the AUC and Cmax/Cmin limitations in claims 2 and 8.
Whether fed and fasted exposure ratios fall within claim 25.
Whether the asserted claims are enabled across their full breadth.
Whether prior art discloses the claimed combination of formulation structure and PK performance.

A settlement agreement could permit a generic launch before patent expiration, but the existence, terms, and launch date of any settlement must be established from the relevant court docket, FTC settlement materials, FDA approval history, and company disclosures. The patent number and claim text alone do not establish a settlement or litigation outcome.

What generic launch scenarios are most plausible?

Scenario	Product design	Patent risk
Same osmotic architecture	22 mg core, cellulose acetate membrane, sorbitol osmagen	High
Same design with altered coating porosity	Osmotic core but modified dissolution	Medium to high
Non-cellulosic membrane	Osmotic delivery with another water-insoluble polymer	Medium
Hydrophilic matrix tablet	Diffusion or erosion-controlled release	Lower against these claims
Multiparticulate capsule	Pellets or coated beads	Lower, unless PK claims are met with equivalent structure
Lower-strength product	Dose below 22 mg	Lower for literal infringement of these claims
Different exposure profile	Once daily but outside claimed PK ranges	Lower, subject to structural claim analysis

The highest-risk design is a direct copy of a 22 mg osmotic tablet using a cellulose acetate membrane and a PK profile engineered to match immediate-release tofacitinib twice daily.

How does this patent compare with immediate-release tofacitinib protection?

Immediate-release tofacitinib patents generally focus on the active compound, pharmaceutical compositions, and methods of treatment. U.S. Patent 10,639,309 is different. It is a drug-delivery patent directed to sustained release and once-daily pharmacokinetics.

Issue	Immediate-release protection	U.S. Patent 10,639,309
Primary subject matter	Compound, composition, or treatment method	Extended-release dosage form
Dose focus	May cover broad dose ranges	Specifically centers on 22 mg
Release mechanism	Immediate release	Osmotic sustained release
Key evidence	Chemical identity or treatment use	Dissolution and PK testing
Main design-around	Different compound or use	Different membrane, osmagen, platform, or exposure profile
Generic relevance	Broad product and indication risk	Formulation-specific risk

What manufacturing and intellectual-property barriers apply?

The principal manufacturing barrier is reproducible control of membrane permeability and osmotic release. Critical process variables can include:

membrane thickness;
cellulose acetate substitution level;
pore-former concentration;
coating uniformity;
core hardness and porosity;
osmagen loading;
orifice formation;
drilling or asymmetric membrane processing;
drug-layer homogeneity; and
dissolution variability across manufacturing scale.

A generic may avoid literal infringement through a different manufacturing route, but the final dosage form still controls product-claim analysis. Manufacturing records can also provide evidence of whether the product uses an osmotic system or a cellulose-derivative membrane.

What is the commercial exposure from this patent?

The commercial exposure is concentrated in once-daily extended-release tofacitinib products, particularly products using a 22 mg strength and an osmotic delivery platform. The patent is less likely to block:

immediate-release tofacitinib;
unrelated JAK inhibitors;
lower-dose extended-release products outside the claims;
non-osmotic extended-release systems; or
products with materially different PK behavior.

Revenue exposure depends on the share of tofacitinib sales attributable to the claimed extended-release product, the patent’s enforceable term, Orange Book listing status, generic certifications, and any settlement or authorized-generic arrangement.

Key Takeaways

U.S. Patent 10,639,309 is a formulation and pharmacokinetic patent for once-daily, 22 mg osmotic tofacitinib.
Claims 1, 2, and 8 are the principal independent claims.
Claim 1 uses a defined dissolution profile.
Claims 2 and 8 use AUC, Cmax/Cmin, drug-holiday, and concentration-time limitations.
Cellulose derivatives, especially cellulose acetate, are central to the claimed membrane.
Sorbitol is a specifically claimed osmagen.
The strongest infringement risk applies to a generic that copies the 22 mg osmotic architecture and matches the claimed PK profile.
Matrix, multiparticulate, non-cellulosic, and lower-dose designs offer potential design-around routes.
Patent expiration requires analysis of the full priority chain, terminal disclaimers, patent-term adjustment, and any regulatory extension.
Orange Book listing, Paragraph IV certifications, litigation, and settlement status must be evaluated separately from the wording of the claims.

FAQs

Does U.S. Patent 10,639,309 cover all Xeljanz products?

No. The claims are directed to a specific once-daily, sustained-release dosage form containing 22 mg of tofacitinib or an equivalent salt amount. Immediate-release products and products with materially different formulation or PK characteristics may fall outside the claims.

Can a generic avoid the patent by using a different osmagen?

Potentially. A different osmagen could avoid the sorbitol-dependent claims, but it would not necessarily avoid claims 1, 2, or 8, which broadly require an osmagen and an osmotic delivery mechanism.

Does a different dissolution profile avoid all claims?

No. A different dissolution profile may avoid claim 1, but claims 2 and 8 are based principally on pharmacokinetic performance. The product could remain exposed if it satisfies the independent structural and PK limitations of those claims.

Is cellulose acetate required by every claim?

No. Cellulose acetate is expressly recited in claim 18. The independent claims use the broader term “cellulose derivative.” A product using another qualifying cellulose derivative may still fall within the independent claims.

What is the most important technical design-around strategy?

The clearest strategies are to use a non-cellulosic membrane, a non-osmotic extended-release platform, a dose below 22 mg, or a PK profile outside the claimed exposure and concentration ranges. Each strategy requires analysis against every limitation of the asserted claims.

References

U.S. Patent No. 10,639,309. (2020). Sustained release dosage forms comprising tofacitinib. United States Patent and Trademark Office.
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. U.S. Department of Health and Human Services.
U.S. Food and Drug Administration. (2024). Xeljanz (tofacitinib) prescribing information. Pfizer Laboratories.
Hatch-Waxman Act, 21 U.S.C. § 355(j).
Patent Act, 35 U.S.C. § 271(e)(2).

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Pfizer	XELJANZ XR	tofacitinib citrate	TABLET, EXTENDED RELEASE;ORAL	208246-002	Dec 12, 2019	AB	RX	Yes	Yes	10,639,309*PED	⤷ Start Trial			Y		⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	095487	⤷ Start Trial
Australia	2014233850	⤷ Start Trial
Australia	2017203334	⤷ Start Trial
Brazil	112015020453	⤷ Start Trial
Canada	2905604	⤷ Start Trial
Canada	3037328	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 10,639,309

Which drugs does patent 10,639,309 protect, and when does it expire?

Summary for Patent: 10,639,309